If you are interested in having your voice heard on BioPharma Dive's Opinion page, please read our editorial guidelines and fill out the submission form here.

• 

  The 2018 biosimilar litigation landscape: A primer

  Even though nine biosimilars are approved in the U.S., lawsuits are keeping most of the copycat biologics off the market. 

  By Michael Cottler, Joshua Whitehill, Alison Siedor • Dec. 14, 2017

• 

  The digitalization productivity bonus in pharma manufacturing

  Digitalization and data analytics can help companies in the sector reduce the high levels of downtime typically experienced by pharmaceutical plants.

  Chris Wilkinson • Aug. 31, 2017

• 

  J&J: Embrace change to transform healthcare supply chains

  J&J's Chief Supply Chain Officer explains how incorporating outside insights and tapping digital innovation has made the pharma giant's value chain more responsive and nimble.

  Kathryn Wengel • June 15, 2017

• 

  The perils of building clinical trials on a shaky foundation

  With the odds stacked against clinical trial success, drug developers need all the tools in their arsenal to make sure they recruit patients quickly and design trials effectively. 

  Craig Morgan • June 1, 2017

• 

  How track-and-trace can revolutionize business

  The concept of tracking-and-tracing, or serialization, was initially developed for a specific purpose – battling counterfeit drugs – but this technology shows promise to be useful for much more.

  Allen Jacques and Dilip Tavargeri • May 4, 2017

• 

  Building a lab when constrained by space

  Kendall Square has become a thriving hotspot for biotech and pharma, but real estate is both expensive and limited. Accelerated Commercialization Spaces offer companies a cost-friendly alternative. 

  Seth Taylor • April 20, 2017